novo nordisk oral semaglutide brand name The U.S. Food and Drug Administration approved Nordisk's (Wegovy) as the first GLP-1 pill for obesity and cardiovascular risk reduction, with the company targeting an early 2026 launch. Novo RYBELSUS® (semaglutide) tablets 7 mg
Pay in 4 interest-free payments of $5.00 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1









:max_bytes(150000):strip_icc()/GettyImages-1299286851-18ab6e02931940ad963dda93851b6dc7.jpg)

















